Cancer Institute A national cancer institute
designated cancer center

Need assistance? Contact the Stanford Cancer Clinical Trials Office at 650-498-7061 or ccto-office@stanford.edu.

Ofrecemos Asistencia en Español.


Search all open clinical trials at Stanford online.

New mobile clinical
trial search app!

iTunes | Google Play


Are you thinking of entering a clinical trial? Learn more here.

Español | 中文 | Pусский


View stories from Cancer Clinical Trial participants at Stanford.

Español | 中文 | Pусский

   

TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma

This phase I/II trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with low-grade B-cell lymphoma that has returned. Monoclonal antibodies, such as ipilimumab, may block cancer growth in different ways by targeting certain cells. Biological therapies, such as TLR9 agonist SD-101, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving ipilimumab in combination with TLR9 agonist SD-101 and radiation therapy may be a better treatment for B-cell lymphoma.


Stanford Medicine Resources:

Footer Links: